Cancer Signaling and Experimental Therapeutics Program
Program Leader - Aliasger K. Salem, Ph.D., Associate Professor, Pharmaceutics
Program Co-Leader - Raymond J. Hohl, MD, PhD, Professor, Internal Medicine and Pharmacology
The overall organizational goal of the Cancer Signaling and Experimental Therapeutics Program is to facilitate the application of recent advances in our understanding of cell signaling, cell cycle control, and apoptosis, to the development of new pharmacologic approaches to cancer prevention and therapy.
Investigators in this program are working on problems that extend from fundamental molecular questions involving signaling pathways to those involving the design of novel compounds based on our growing knowledge of molecular aspects of cell biology. Such laboratory scientists collaborate with other members of the Program who are clinical investigators with a broad range of backgrounds and expertise in performing innovative clinical cancer trials.
The program includes basic and clinical investigators from multiple departments at the University of Iowa, and has members who have primary appointments in the Colleges of Medicine, Pharmacy, and Liberal Arts.
Members of the Cancer Signaling and Experimental Therapeutics Program
Research Program Membership Guidelines